

APR 2 2 2002

APR 2 2 2002

APR 2 4 2007

TECH GEARDEAN (10-01)

Approved for use through 10/31/2002 (MMc4951-093h)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCIE 2000

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Control number.

Substitute	e for form 1449A/	РТО		Complete if Known		
				Application Number	10/0050,376	
INFO	RMATIO	N DIS	CLOSURE	Filing Date	01/16/2002	
STAT	<b>TEMENT</b>	BY AF	PPLICANT	First Named Inventor	Uwe Joerg RIES	
				Art Unit	-1614- 1602 (a	
(	use as many sl	heets as n	ecessary)	Examiner Name	K. Anderson	
Sheet	1	of	1	Attorney Docket Number	5/1312	

			U.S. PAT	ENT DOCUMENTS	
Examiner Initials		Document Number Number - Kind Code <sup>2</sup> (if known	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		us-			
		us-			
		US-	-		
		us.			
	İ	us-		·	
	Ì	us.			
	i .	us-			ĺ
	i	us-		i i	•
	i	us-			
		US-		i*	i
		us-		,	
		US	• • • • • •		• •
		US-			1
	1	US-			• • •
	-	us-	•		
1		• •			
		US-			
	با	US-		-	
į.		US-		-	
٠.,		U <u>\$</u> -			<u>-</u>
		us-			

		FOR	EIGN PATENT D	OCUMENTS		
Examiner Initials	Cite No.1	Foreign Patent Document  Country Code 3 *Number* - Kind Code * (# Innown)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
RECEI		WO 01 10823 WO 00 71508 WO 00 71512	02/15/2001 11/30/2000 11/30/2000	BI Pharma KG COR Therapeutics COR Therapeutics		
			- - 			

Examiner Considered Signature

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check merk here if English language Translation is attached.

engish language i rensiation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08A (02-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

stitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

1 for use through 04/30/2003.
COffice; U.S. DEPARTMENT OF C.L.
Unless it contains a valid OMB control num.

plet if Known

10/050,376

January 16, 2002

Ries, U. et al Complet if Known Application Number Filing Date First Named Inventor Art Unit Examiner Name Attorney Docket Number

			U. S. PATENT D	OCUMENTS	7
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>Z (# known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	ļ	US-			Figures Appear
		<u>L</u>			1
		US-			
		ÚS-			
		US-		**************************************	
		US-			
		US-			
		US-	<u> </u>		

		FORE	IGN PATENT DOCU			
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,	$\Gamma$
muais	No.		Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages	-3
<i>_</i>		Country Code <sup>3</sup> Number <sup>4</sup> Kind Cade <sup>5</sup> (if known)	WING-CID-1111		Or Relevant Figures Appear	[ '
/CAL		WO 96/40100	12-19-1996	3-Dimensional Pharm.		
P		WO 00/56707	09-28-2000	Sepracor, Inc.		Г
PS		WO 02/04403 A1		Boehringer Ingelheim		Г
126_		GB 2007663		VEB Arzneimittelwerk		Г
R		EP 0654465	05-24-1995	CIBA-GEIGY AG		

Signature

PEXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gog/">www.uspto.gog/</a> or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3.) For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-726-9100) conference.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

e sono	the Paperwork Re	eduction Ac	at of 1995, no persons a	U.S. Patent	and Trademark Office; U.S. DE		
1.5	te for form 1449/PTO				Compl to if Kn wn	MES	
				Application Number	10/050,376		
INFO	DRMATION	N DIS	CLOSURE	Filing Date	January 16, 2002	APR	
STA	TEMENT I	BY A	PPLICANT	First Named Inventor	Ries, U. et al	ECHO	2003
	(Use as many sh		20000000	Art Unit	1614 1626	CNIFO	1003
	(Use as many sn	1661\$ 25 77		Examiner Name	R. Anderson	16	0/200
Sheet	2	of	2	Attorney Docket Number	5/1312	<del></del>	0/2900

		OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS								
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.								
PA		LABES, D. and HAGEN, V. "Free-Wilson-Analyse der Hemmwirkung von 4-substituierten Benzamidinen gegenueber Thrombin, Plasmin und Trypsin" Pharmazie, 1979, 34(9):554-555								
Bb		TAMIZ, A.P. et al "A Convenient Procedure for the Syntheses of Nonsymmetrical Bivalent Selective Serotonin Reuptake Inhibitors Using Polymer-Supported Reagents" Bioorganic & Med. Chem. Ltrs, 2000, 10:2741-2743.								
Ph		VALENTI, et al, "Cyclovinylogs of procainamide" Chemical Abstracts, 1983, 98(7):620								
Ph	Database Crossfire Beilstein, Beilstein Instutue Zur Foerderung Der Chemischen Wissenschafter, Frankfurt AM Main, DE									

Examiner	1	/\ /		Date	1 20		
Signature	ellen	Mad	lon	Considered	18/2	0103	
ACMANINGO, I-M-I	Market Comments						

EXAMINER: Initial if reference considered, whether of not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing his burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.